Orthocell achieves first Remplir™ sales in US$75 million Canadian Market
Orthocell has shared that it has completed the first commercial sales of Remplir™ in Canada, marking a key milestone in the Company’s global commercialisation strategy for its flagship nerve repair medical device. The first sales follow regulatory approval from Health Canada for Remplir and distributor appointments in 2H CY25, which currently provide the majority of national coverage across the Canadian market and position […]
Orthocell reports continued growth and strong US momentum in March 2026 quarter
Orthocell (ASX:OCC) has released its Quarterly Report for the quarter ended 31 March 2026, highlighting continued revenue growth, strong commercial traction in the United States, and expanding global adoption of Remplir™.
First Remplir™ Surgical Case Completed in U.S. Department of Defense Hospital Network
Orthocell has shared that the first surgical case using Remplir™ has been successfully completed within the U.S. Department of Defense (DoD) / Veterans Affairs (VA) hospital network, shortly after the Company announced approval to supply Remplir into these hospital systems.
Remplir™ Exempt from US Pharma Tariffs Due to Medical Device Status
Recent coverage has highlighted that Orthocell’s flagship nerve repair product, Remplir™, is expected to be exempt from newly proposed US tariffs targeting pharmaceutical imports.
Investor Presentations | March 2026
Orthocell CEO and MD, Paul Anderson, presented at two investor-facing events on 31 March 2026, providing an in-depth update on the Company’s commercial progress and global expansion strategy.
Remplir™ Used in 23 Surgeries on Injured Soldiers in Ukraine
Orthocell has announced that its Remplir™ nerve repair device has been used in 23 surgical procedures on injured soldiers in Ukraine.